Medicine and Dentistry
Cohort Analysis
51%
Proton-Pump Inhibitor
48%
Malignant Neoplasm
48%
Melanoma
48%
Thyroid Cancer
48%
Glucagon-Like Peptide-1 Agonist
48%
Postmenopause
48%
Pancreas Cancer
48%
Hormone Substitution
48%
Pharmacoepidemiology
48%
Gabapentinoid
48%
Odds Ratio
47%
Hazard Ratio
18%
Dose Response
16%
Pregabalin
13%
Gabapentin
13%
Case-Control Study
13%
Tumor Promoter
12%
H2 Antagonist
10%
1,1 Dichloro 2,2 Bis(4 Chlorophenyl)ethane
10%
Cancer Risk
10%
Patient with Type 2 Diabetes
9%
Dipeptidyl Peptidase-4 Inhibitor
9%
Logistic Regression Analysis
8%
Clinician
7%
Reassurance
7%
Proportional Hazards Model
7%
Population Research
7%
Prevalence
6%
Treatment Duration
6%
Benzodiazepine Derivative
6%
Localized Disease
6%
All Cause Mortality
6%
Cancer Registry
5%
Health Care
5%
Cancer Diagnosis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Case-Control Study
100%
Replacement Therapy
48%
Lung Cancer
48%
Breast Cancer
48%
Melanoma
48%
Antithrombocytic Agent
48%
Dipeptidyl Carboxypeptidase Inhibitor
48%
Drug Utilization
48%
Gabapentinoid
48%
Defined Daily Dose
25%
Acetylsalicylic Acid
22%
Dipyridamole
17%
Pregabalin
13%
Gabapentin
13%
Clopidogrel
13%
Thiazide Diuretic Agent
10%
Cohort Study
8%
Malignant Neoplasm
7%
Prevalence
6%
All Cause Mortality
6%
Diseases
6%
Cancer Mortality
5%
Angiotensin Receptor Antagonist
5%
Biochemistry, Genetics and Molecular Biology
Case-Control Study
48%
Low Drug Dose
48%
Glucagon-Like Peptide 1 Receptor
48%
Cohort Study
48%
Receptor Agonists
48%
Clopidogrel
29%
Dose Response
19%
Thrombocyte Aggregation
9%
Estrogen Receptor
9%
Dipeptidyl Peptidase-4
9%
Anticancer
9%
